Global Age-Related Macular Degeneration (AMD) Therapeutics Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Age-Related Macular Degeneration (AMD) Therapeutics Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Age-related macular degeneration is a bilateral ocular condition in which the central area of the retina, known as the macula, is affected.
Age-Related Macular Degeneration (AMD) Therapeutics report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Age-Related Macular Degeneration (AMD) Therapeutics market is projected to reach US$ 11400 million in 2034, increasing from US$ 7725.7 million in 2022, with the CAGR of 5.8% during the period of 2024 to 2034. Demand from Hospital and Clinic are the major drivers for the industry.
Age-related macular degeneration is a progressive condition, and it is common among the geriatric population. The growing geriatric population is contributing to the rising incidence of age-related macular degeneration globally. As a result, there is a high demand for therapeutics to treat the condition. Pharmaceutical companies are leveraging this opportunity and are focusing on releasing drugs to treat age-related macular degeneration.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Age-Related Macular Degeneration (AMD) Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Amgen Inc.
Bausch Health Companies, Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
Regeneron Pharmaceuticals Inc.
Segment by Type
Wet AMD
Dry AMD
Hospital
Clinic
Research Institute
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Age-Related Macular Degeneration (AMD) Therapeutics market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Age-Related Macular Degeneration (AMD) Therapeutics introduction, etc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Age-Related Macular Degeneration (AMD) Therapeutics market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Age-Related Macular Degeneration (AMD) Therapeutics report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Age-Related Macular Degeneration (AMD) Therapeutics market is projected to reach US$ 11400 million in 2034, increasing from US$ 7725.7 million in 2022, with the CAGR of 5.8% during the period of 2024 to 2034. Demand from Hospital and Clinic are the major drivers for the industry.
Age-related macular degeneration is a progressive condition, and it is common among the geriatric population. The growing geriatric population is contributing to the rising incidence of age-related macular degeneration globally. As a result, there is a high demand for therapeutics to treat the condition. Pharmaceutical companies are leveraging this opportunity and are focusing on releasing drugs to treat age-related macular degeneration.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Age-Related Macular Degeneration (AMD) Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Amgen Inc.
Bausch Health Companies, Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
Regeneron Pharmaceuticals Inc.
Segment by Type
Wet AMD
Dry AMD
Segment by Application
Hospital
Clinic
Research Institute
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Age-Related Macular Degeneration (AMD) Therapeutics market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Age-Related Macular Degeneration (AMD) Therapeutics introduction, etc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Age-Related Macular Degeneration (AMD) Therapeutics market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices